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ABSTRACT 
Disorders of lipid metabolism and obesity are reported by 30% to 40% with increased 
prevalence. These conditions are co-related with Medo-pradoshajavikara - a condition leading for excess 
formation of Meda (lipids) directly from Amarasa Dhatu (improperly formed chyle) and travel all over 
body through blood circulation. This stage is compared to hyperlipidaemia where it is defined as excess 
circulation of lipids in blood. The present study highlights the efficacy of Ooshakadi Lekhana Basti (type of 
therapeutic enema) processed by Ooshakadigana Dravyas (alkaline substances). Ooshaka (alkaline sand) 
was special drug and used almost for first time which is synonymously known as Kshara Mrittika. A single 
blinded controlled study has been conducted on 45 patients randomized in to three groups each 
containing 15 patients. The control drug was atrovastin. Average mean reduction of lipids were found 
statistically significant (p<0.05) in the experimental groups over control group in all types of lipids except 
HDL which has presented increase pattern. Hence the study establishes the efficacy of Ooshakadi Lekhana 
Basti in hyperlipidaemia of obese and non-obese patients. 
KEY WORDS: Hyperlipidemia, Obesity, Medopradoshaja Vikara, Ooshakadi Lekhana Basti, Ooshaka, Kshara 
Mrittika. 
INTRODUCTION 
In the present era, sedentary life style, 
unbalanced diet and stressful mental conditions leading 
to fatal diseases, resulting in irreversible complications. 
Disorders of lipid metabolism are increased with 
incidence of prevalence by 30% to 40%1 due to gross 
changes in life style and food habits. It is most relevant 
to the population as a whole when compared to the 
other major modifiable coronary risk factors namely 
smoking and hypertension. Risk is higher at an age of 65 
and above due to cumulative effect on cholesterol 
metabolism. Increased level of cholesterol at the age of 
35 increases the risk of heart disease much more 
significantly than with same level at the age of 65. 
Framingham heart study reveals that, men are about 
three times more susceptible to develop heart diseases 
than women. After menopause women become more 
prone to develop C.H.D. with high levels of cholesterol. 
Conditions must be detected early and treated 
preventing the clogging of the arteries. The impact of a 
medical intervention should be judged through the top 
which it influences or ensures the long term wellbeing of 
a patient. This criterion of long term welfare of patient is 
being ignored in the present modern system. The 
practitioners of this system are not really satisfied when 
they face chronically frustrated patient with serious side 
effects. Therefore now–a-days global interest is 
developing towards alternative medicine, especially 
Ayurveda to face this challenge as it protects patients 
against such frustration. 
NEED AND SIGNIFICANCE 
Reports are now available of angio-graphically 
evaluated trials of lipid lowering strategies and drugs in 
patient with hyperlipidaemia and known coronary 
artery disease. These studies have conclusively 
documented a marked decrease in the progression of 
coronary atherosclerotic lesions, modest regression and 
a moderate reduction in coronary events. Several drugs 
are available for the management of hyperlipidaemia. 
Most of the drug used in this condition are potentially 
toxic, costly and are contraindicated in hepatic or renal 
impairment, gall bladder disease and pregnancy. 
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Adverse effect of these drugs include reversible myositis, 
non-specific malaise, impotence, gall stone formation 
etc., At this juncture Ayurveda can intervene by 
modifying the risk factors aiming at the prevention of 
CAD. 
Hyperlipidaemia can be correlated to 
Medopradoshaja vikara (disorder of improper lipid 
metabolism). It is a condition caused by derangement of 
Agni (digestive fire), that leads to formation of 
Amaannarasa(improper formation of chyme). The 
Amarasa with Madhura Rasa Bhavadhikya (increased 
sweet taste) is similar to Kapha and Meda Dhatu (lipid 
tissue). This undergoes unique manifestation of Dhatu 
Davyamti Kramyam pathology (direct conversion of 
Aama Rasa in to Meda Dhatu avoiding formation of 
Rakta (blood tissue) and Mamsa (muscle tissue)). This 
causes abnormal excess formation of Meda which will be 
sent for circulation2. This particular stage is correlated 
with hyperlipidaemia, which has increased circulated 
lipids in the blood. In later stages if pathology is not 
arrested, it is believed that lipids get deposited in the 
localized areas or all over the body resulting in the 
formation of adipose tissue and called as sthoulya3. Many 
therapeutic measures were mentioned in classics but 
basti (therapeutic enema) has got very prominent role in 
this pathology. Though it is a prime treatment for vata it 
also acts on pitta, kapha, rakta and sannipataja vyadhis 
(combination of all doshas)4 with diversified actions by 
multiple combinations and permutations.5Here the type 
of basti is “Lekhana Vasti”6 with “OoshakadiGana 
Dravyas”7. Here all the drugs possess qualities opposite 
to Meda Dhatu and Teekshana (most potent) in nature, 
Tejo Guna Pradhana (predominant of increasing the 
ability of digestive fire). This increases the Jataragni 
leading to metabolism of Snigdhamsha (unctuous) Meda 
and Rukshana (drying) of Meda, by Lekhana (scraping) 
and Chedana (dissipating / clearing) action because of 
which the Meda in circulation will be decreased.  
With this classical background this study is planned to 
find the role of Ooshakadilekhana Basti in the 
management of Medopradoshajavikara w.s.r to 
hyperlipidaemia. 
AIMS AND OBJECTIVES 
 To evaluate the role of Ooshakadi Lekhana Basti in 
the management of Medopradoshaja Vikara w.s.r to 
hyperlipidaemia. 
 To ascertain the lowering of lipid levels in obese 
patients and non-obese patients. 
 To compare the efficacy of Ayurvedic Panchakarma 
procedure -Lekhana Vasti with an allopathic anti-
hyperlipidaemic drug. 
MATERIALS AND METHODS 
Procurement of Raw materials 
1. This includes the collection of raw materials required 
for the formulation of “Ooshakadi Lekhana Basti”. 
2. Preparation of the MoorchitaTila Taila (processed 
sesame oil, Triphala Kashaya (decoction of Triphala), 
Ooshaka (alkaline sand ash ), Yavakshara (ash of 
barleyplant), Shodhana (purification) of 
Aavapadravyas (metallic substances) and collection 
of Gomootra (cow’s urine) required for Basti 
3. Systematic preparation of the amalgamation of 
Nirooha Basti Yoga8 called “Ooshakadi Lekhana Basti”. 
1. MoorchitaTila Taila : Drugs required for Moorchana 
are collected and tila tila is processed according to 
the classical reference in order to remove bad odour 
and make devoid of Amadosha lakshanas (toxic 
properties)9. 
2. Triphala Kashaya: Equal quantity by weight of 
Amalaki (Emblica officinalis), Haritaki and Vibhitaki 
(Terminalia chebula) were powdered and mixed. 1 
part of above powder was taken with 16 parts of 
water and reduced to ¼th of it to prepare Triphala 
Kashaya.10 
3.   Yavakshara& Aavapa Dravya: Yavakshara & Aavapa 
Dravyas (except ooshaka) were procured directly from 
Manjeri Pharmacy, Hukkeri. Aavapa Dravyas included 
in the formulation are 
I. Ooshaka 
II. ShuddhaShilajitu 
III. Shuddha Kasisa 
IV. ShuddhaTutta 
V. ShuddhaHingu 
VI. Yavakshara & Sarjakshara (due to unavailability of 
Sarjakshara; Yavakshara was added in the 
proportion of 2 parts). 
4. Preparation of Ooshaka: Ooshaka was considered 
as Ooshara Kshara which is having synonym of 
Shilajatu. But literal meaning of this drug is Kshara 
Mritika. The senile sand was collected which is 
called TouduMannu in local languages. This was 
processed according to Ksharavidhi as specified in 
the classical text “Rasajalanidhi”11  
5. Fresh Gomutra was collected which passed for first 
time in the morning from a healthy cow and filtered. 
6. Preparation of Niroohavasti Yoga: The following 
ingredients were collected and triturated in the 
same order with uniform direction, pressure and 
speed12 
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Table 1: Ingredients used for Nirooha Basti
S.No Name of ingredients Actual Dose Altered Dose 
1. Makshika(Honey) 1 pala = 46 ml 11.5ml 
2. SaindhavaLavana(Rock salt)  1 aksha = 12 g 6 g 
3. Sneha =Moorchitatila taila (Sesame oil) 6 pala = 288 ml 72ml 
4. Kalka = Yavakshara 3 pala = 144 g 36g 
5. 
 
Drava dravya = Triphalakwatha 
Gomutra 
5 pala = 240 ml 200ml 
3 pala=144 ml 50ml 
6. Aavapa dravya = Ooshakadigana dravyas 1pala X 6 = 268 g 6-7 g 
7. Total 24 palas 6palas= 300ml 
7. Anuvasana Basti (retention enema): 
MoorchitaTila Taila was used for the administration of 
Anuvasana Basti. 
Materials or tools for therapeutic intervention: 
 Basti yantra and Basti putaka (Devoid of Doshas) 
 Basti yantra includes enema can and catheter of 
suitable size for administration of Nirooha Basti 
 Glycerene enema syringe with catheter was used for 
administration of Anuvasana Basti 
METHODOLOGY 
Clinical study 
Research approach 
In the present study, the objective is “Role of 
Ooshakadi Lekhana Basti in management of 
Medoprdoshaja Vikara w.s.r. hyperlipidaemia”. The 
efficacy can be determined by finding out difference 
between experimental group and control group. 
Study design: Randomized Controlled clinical study 
Source of Patients: Patients attending O.P.D and I.P.D of 
Sri Jayachamarajendra Institute of Indian medicine, 
Bangalore. 
Inclusion Criteria 
 Patients aged between 18-60 years of both sexes 
presenting with hyperlipidaemia (increase of all 
types of lipids). 
 Hyperlipidaemia with or without obesity 
 Patients who are eligible for Basti Karma according to 
classics.[13] 
Exclusion Criteria 
 Patients with systemic disorders like diabetes 
mellitus, diabetes insipidus, coronary artery 
disorders etc.  
 Patients being obese due to other conditions like 
endocrinal disorders, hormonal therapy etc. 
 Patient with any rectal pathology like piles, fistula, 
fissure, carcinoma. 
Consent: Informed consent was obtained from the 
patient before starting the study.  
Grouping: 
Patients were selected for the trail studied under three 
groups, each containing 15 Patients. Group “A” & group 
“B” are experimental groups and group “C” is Control 
group.  
Group A: Patients with hyperlipidaemia, associated with 
obesity. 
 Kalabasti with 6 Nirooha Basti and 10 Anuvasana 
Basti was administered. Pariharakala (Time period to 
be on rest) was advised for double the duration of 
administered period of basti i.e. 20 days. 
Group B: Patient with hyperlipidaemia and not 
associated with obesity. 
 Kalabasti with 6 Nirooha Basti and 10 Anuvasana 
Basti was administered. Pariharakala (Time period to 
be on rest) was advised for double the duration of 
administered period of basti i.e. 20 days. 
Group C: Patients with hyperlipidaemia with or without 
obesity were administered with an anti hyperlipidaemic 
drug called atrovastin. Dose was depended on the lipid 
levels. 
Method of assessment: 
 Evaluation of lipid profile for all groups was advised 
1 day before and 20 days after the administration of 
treatment. 
Grading of Lipid profile assessment 
 All lipid profile in normal limits with increased H.D.L– 
Good response. 
 All lipids profile in normal limits with decreased 
H.D.L– Moderate response. 
 Increase in all lipid parameters with H.D.L increase – 
Mild response. 
 All lipids increased with H.D.L decrease – Poor 
response. 
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Table 2: Schedule of Administration of Basti
Part of the Day 1 2 3 4 5 6 7 8 9 10 
Morning (Empty Stomach)  NB NB NB NB NB NB    
After Food AB AB AB AB AB AB AB AB AB AB 
NB = Nirooha Basti, AB = Anuvasana Basti 
Mode of Administration of Basti 
Anuvasana basti alone was administered on first 
and last three days. Alternative administration of 
Nirooha and Anuvasana basti performed from second 
day to seventh day. Nirooha Basti was administered in 
empty stomach. After basti Pratyagamana (expulsion of 
Basti Dravya), Laghu Aahara (light food) was given for 
consumption and immediately Anuvasana Basti was 
administered. 
Method of Administration 
Poorva Karma (pre-operative) 
 Above mentioned materials were collected. 
 Preparation of Enema can and catheter attached 
without any defects. 
 Aatura Siddha (Patient concern activities) – Patients 
visited to hospital with empty stomach. Sthanika 
Abhyanga (local oleation) to Udara (abdomen) & 
Sphik (gluteal region) with Moorchitatila taila 
(sesame oil) followed by SthanikaNadiSweda (local 
sudation) with Dashamoola Siddha Kwatha 
(decoction processed by Dashamoola). 
 Ooshakadi Lekhana Basti SammelanaVidhi 
(preparation of Nirooha Basti Yoga)-  
 The different components of basti were mixed in the 
following way. Dose of different drugs were 
considered according to strength of patient as 
explained earlier. 
 1st step – Madhu and saindhava lavana were 
triturated thoroughly in Khalwa Yantra. 
 2nd step – Then Moorchit Tila Taila was added 
mixed slowly and uniformly. 
 3rd step –Yavakshara added little by little and 
triturated.  
 4th step – Fresh and clasically prepared Triphala 
Kwatha was added gradually. 
 5th step –Gomutra to be added after proper mixing 
of Kwatha. 
 6th step – The above mentioned Aavapa dravyas 
are sprinkled in the final amalgamation.  
This unique preparation was attained without 
sedimentation. Triturating was performed in unilateral 
direction, pressure and speed by same person. The 
amalgamation was indirectly heated to luke warm 
temperature.  
Pradhana karma (operative procedure) 
Position of patient: Patient was advised to lie on the 
table in Vama Paarshwa (left lateral position with right 
leg flexed) and asked to take deep breath with left hand 
beneath head. The rectal orifice was anointed with 
cotton gauge dipped in luke warm oil. 
Basti Yantra with Basti Dravya: Sukoshna Basti Dravya 
was filled in to the enema can and care was taken for 
removing air from the catheter. Proper lubrication of 
catheter was performed. 
Basti Pranidhana (Administration of Basti): Sukoshna 
Vasti Dravya was administered gradually with uniform 
speed. Care was taken that medicine was not 
administered completely at the end. Vasti Vyapaths are 
avoided by taking proper care. The time of 
administration was noted and checked for any 
complications during procedure. 
 Basti Pratyagamana: Pratyagama Kala (time of 
expulsion of administered contents) was recorded. 
Maximum retention period was 3-4 minute. 
Paschat karma (post-operative): Patient was advised 
to maintain diet regimen in Vasti Parahara Kala. 
RESULTS
Table 3: Over All Mean Assessment of Lipid Profiles in all Groups 
OBJECTIVE Gropu-A Group-B Group-C 
 BEFORE AFTER BEFORE AFTER BEFORE AFTER 
T.Cholesterol 227.85333 190.806666 242.0666 200.7333 236 209.7 
Triglycerides 210.68666 166.95333 187.9333 141.8666 162.4 122.2 
HDL 46.83333 48.36 50 52.857 42.9 39.3 
L.D.L 138.73333 119.53333 146.4 123.2 156.666 132.866 
V.L.D.L 40.3285 31.0000 38.0933 30 33.0333 28.0933 
Chol:H.D.L 5.01 4.0333 4.915 4.15 5.341 5.008 
 
Table 4: Showing the individual study of group 1 by using paired t-test 
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Parameter Mean SD  SE t-value p-value Remarks 
Total cholesterol 37.4466 33.5609 8.665 4.3215 <0.001 H.S 
Triglycerides 60.2660 52.1213 13.457 4.478 <0.001 H.S 
H.D.L 4.4733 2.3398 0.6041 7.4048 <0.001 H.S 
L.D.L 19.2 23.683 6.11 3.142 <0.001 H.S 
V.L.D.L 11.6266 13.5858 3.5078 3.3144 <0.005 H.S 
Table 5: Showing the individual study of Group 2 by using paired t-test 
Parameter Mean SD  SE t-value p-value Remarks 
Total cholesterol 47.866 37.3016 9.631 4.97 <0.001 H.S 
Triglycerides 47.4 35.192 9.0867 5.2164 <0.001 H.S 
H.D.L 7.8666 4.7639 1.23 6.3956 <0.001 H.S 
L.D.L 23.2 30.599 7.9 2.936 <0.001 H.S 
V.L.D.L 8.36 6.6117 1.7071 4.897s <0.005 H.S 
Table 6: Showing the individual study of Group 3 by using paired t-test 
Parameter Mean SD  SE t-value p-value Remarks 
Total cholesterol 35.766 29.767 7.6859 4.653 <0.001 H.S 
Triglycerides 42.466 30.2486 7.810 5.437 <0.001 H.S 
H.D.L 8.1 5.676 1.4656 5.526 <0.001 H.S 
L.D.L 23.8 29.737 4.911 3.099 <0.001 H.S 
V.L.D.L 9.1466 7.897 2.0391 4.485 <0.001 H.S 
Table 7: Showing ANOVA table for parameter H.D.L 
Source of 
variation 
Degrees of 
freedom 
Sum of 
squares 
Mean sum 
of squares 
F-calculated 
Value 
F-Table 
Value 
P-Value Remarks 
Treatments 2 1503.409 751.7045 
5.581 3.23 <0.05 H.S Error 42 5656.783 134.685 
Total 42 7160.1972  
Table 8: Shows which group is significant for the parameter 
Group Difference from Difference from Difference from 
2 53.333* ----------  
1 48.36* 4.97  
3 39.366* 13.946* 8.994* 
Table 9: Showing ANOVA table for parameter triglycerides 
Source of  
variation 
Degrees of 
freedom 
Sum of 
squares 
Mean sum 
of squares 
F-calculated 
Value 
F-Table 
Value 
P-Value Remarks 
Treatments 2 15094.89 7547.445 
2.7218 3.23 <0.05 H.S Error 42 116461.19 2772.88 
Total 44 131556.08  
Table 10: Shows which Group is significant for the parameter 
Group Difference from Difference from Difference from 
3 122.2 ---------- ----- 
2 141.866 -19.666 ------ 
1 166.953 -44.753 ------ 
Table 11: Showing ANOVA table for parameter V.L.D.L 
Source of  
variation 
Degrees of 
freedom 
Sum of 
squares 
Mean sum 
of squares 
F 
calculated 
Value 
F 
Table 
Value 
P-Value Remarks 
Treatments 2 328.400 1.642 
1.453 3.23 <0.05 H.S Error 42 4745.54 112.989 
Total 44 5073.94  
Table12: Shows which group is significant for the parameter 
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Group Difference from Difference from Difference from 
3 24.793 ---------- ----- 
2 30.00 -5.207 ------ 
1 30.933 -6.14 ------ 
 
Statistical analysis 
  To compare the mean effect of the 
treatments the statistical analysis was done by using F-
test by assuming a completely randomized design and 
for the analysis purpose the mean effect was same in all 
the three groups. Further to know which pair of 
treatment is significant the analysis was done by using 
Least Significance Different method (L.S.D). To compare 
control group and experimental groups the statistical 
analysis was done by using Dunnets’s test. To know the 
effect of the treatment procedure within the control and 
experimental groups the statistical analysis was done by 
assuming that the treatment procedure is not 
responsible for the changes in the observation before 
and after the treatment. Further to know which group is 
more effect in treatment procedure comparison of t-
values were considered. After thorough analysis of 
results it was observed that group-A and group-B were 
indicating better results over group-C. Among the 3 
groups, group-B was suggestive of better treatment 
effect on lipid profile than group-A & C. 
DISCUSSION 
The present study demonstrates the incidence 
of age group between 41-50(66.6%) years with sexual 
distribution of increased female ratio (60%) pertaining 
to menopausal age. The hormonal imbalance during 
menopausal age or the diet habits interfere in the 
women and are more prone to this disease as relation 
exists between hormones and metabolism of lipids. But 
it’s not possible to conclude the fact because of small 
sample size and limited type of population attending the 
out-patient department. Genetic and chromosomal 
abnormalities in hyperlipidemia are to be considered as 
the study suggests the positive family history of 17.7% 
which infers the role of beeja swabhava14 (genetic factor) 
in concern to Matrujabhava (maternal factor) as Sowmya 
Dhatu (soft tissues like lipid tissues) are contributed by 
them 15. The predisposing factors like Snigdha Dravyas 
(unctuous substances) (44.4%) followed by Sheeta (cold 
in potency) (31.1%) and Guru Dravyas (heavy for 
digestion) (24.4%)16, 17 were present abundantly in diet 
of these patients with typical dietary patterns of 
Adhyashana18 (excess-eating), Vishamashana 
(uncongenial diet) and Samashana (combination of both 
wholesome and unwholesome diet) type. 
Atisampoorana19,20 (eating before the digestion of 
previous food), Ajeernaaahara (improperly cooked food) 
were elicited among the different types of Adhyashana in 
this sample of population as the major causative factors 
for Medovriddhi. The increased occurrence of 
Teekshanagni (increased rate of basal metabolism) 
presentation with 33.3% defines the role of neuro-
transmitters. A number of neurotransmitters afferent 
and efferent signals plays vital role in energy intake and 
metabolism. Decreased sympathetic activity, increased 
level of insulin and disturbed serum leptin concentration 
causes excessive hunger in Medovriddhi. Ayurveda has 
explained this phenomenon in terms of vitiation of Vata 
by obstruction of its path due to Meda leading to 
Tikshnagni. The mentioning of Madhura Rasa as 
important predisposing factor for Medovriddhi can be 
evident by the occurrence of 40% of the study sample 
indulging in the consumption of this type of rasa21. 
Lifestyle and sleep pattern22, 23(day sleep & excess sleep) 
are very important causative factors for vitiation of 
Meda that can be well substantiated with the incidence 
of 33.3% & 22.2% respectively. Here the pathology is 
due abnormal vitiation of Kapha because of day sleep 
and excess sleep. And also the association of kapha as 
inherent factor in pathogenesis of dyslipidemia is 
understood from the type of Prakrutias presented in the 
study sample were kapha-Vata Prakruti (44.4%), Vata-
kaphaPrakruti (33.3%), and Pitta-kaphaPrakruti 
(11.11%). Most of them are associated with Kapha Dosha 
as Pradhana Prakruti which inherits the Medopradoshaja 
Vikara. 
The mean %age of improvement in the Total 
Cholesterol (20.58%), Triglycerides (32.47%), H.D.L 
(5.89%) and L.D.L (18.33%) is more in the Group 2 
(hyperlipidemia without obesity) where as V.L.D.L. 
(33.53%) in Group 1 (hyperlipidemia with obesity). 
From the analysis the parameters H.D.L. shows high 
significance i.e. the mean treatment effect of three 
groups is not same (as p<0.05 from table – 7 & table - 8). 
All the treatment effects are not same. The highest mean 
effect of 53.33 in Group-B, if among choice is to be made 
in three groups then group-B is best and most effective 
in H.D.L. parameter as mean value is more than L.S.D 
value. From the table 9 and 10, of all the three groups 
mean value of first group exceeds control mean value 
significantly; treatment of group-A is good for significant 
effect on Triglycerides. From table 11 & 12 of all the 
three groups mean value of first group exceeds group-C 
mean value significantly; treatment of group-A was 
effective and significant effect on V.L.D.L. Rest of the 
parameter not significant as p>0.05. 
 Student’s paired t-test demonstrates that all 
parameters of group-A shows highly significance from 
table 4 (as p<0.05). Among Lipid profiles the parameter 
H.D.L is highly significant than the other parameters (by 
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comparing t values). From table 5 all parameters of 
group-B show high significance than the other with less 
variation (by comparing t and SD values), where as the 
parameter of total cholesterol shows more net mean 
effect. From table 4 H.D.L parameters of group-C shows 
less variation and total cholesterol indicates net mean 
effect. Further to know which group was more effect in 
treatment procedure comparison of t-values from 
tables-4 was considered. Among the parameters of lipid 
profile total cholesterol was more significant in group-B, 
triglycerides in group-C, H.D.L in group-A, L.D.L in 
group-B and V.L.D.L was highly significant in group-B. 
With above treatment results it is evident that Ooshakadi 
Lekhana Vasti is efficient in management of 
Medopradhoshaja Vikara w.s.r to hyperlipadeamia. 
Probable mode of action of OoshakadiLekhana Vasti 
Basti Karmukata (mode of action) understood at 
different levels of the body like Dosha, Dhatu, Mala and 
in different Roga-margas24 (different routes involved in 
diseases). The multidimensional actions25exerted by the 
Basti are due to the usage of various combinations of 
drugs25. The specific formulation called “Ooshakadigana” 
dravya mainly possesses Katu, Tikta, Kashaya Rasa 
(different inherent tastes of the drugs). Ushna, 
Teekshana, Laghu, Rooksha Gunas are the inherent 
qualities with Ushna Veerya (potency) and Katu Vipaka 
(taste exerted at the end of digestion). These properties 
are Tejo Guna Prahana and are understood to act at the 
level of Jataragni (digestive fire) enhancing the 
Dhatvagni (metabolism). Thus the formation of Ama 
Rasa is avoided and sequential formation of Rasa, rakta 
is achieved resulting in decreased production of 
Medadhatu. Further it will not cause the occlusion 
(Aavarana) of Vata which will not cause increased 
appetite which is usually set-in due to Jataragni deepti. 
Hence avoiding the patient in indulging in the causative 
factors. The Tila Taila administered, in obese persons 
enters minute channels and does Kshapana of Meda by 
the Sukshama, Teekshana, Ushna Gunas and also has 
ability to acquire the properties of the other drugs by 
Samskara. The Moorchita Tila Taila has the Vyavayi Guna 
(fast spreading nature) along with the above specified 
qualities where the absorption is facilitated, carried all 
over the body performing the required function of 
Lekhana (scraping) and Rookshana (drying) leading to 
Nasha of Meda (cleansing the accumulated lipids).The 
Kshara Guna (alkaline property) effect of Gomutra, 
Yavakshara is increased by the synergistic effect of 
Ooshakadi Gana drugs as they also possess similar 
properties. The complete and final product of Nirooha 
Basti is a hyper tonic solution. After entering in the large 
intestine it creates the osmotic pressure gradient, 
favoring the body fluids transfer from hypotonic to 
hyper tonic solutions along with toxic materials like LDL 
cholesterol. This phenomenon preferably helps to drag 
the toxins (unwanted metabolites) from inter intra 
cellular levels to large intestine and are eliminated out of 
body. This LDL cholesterol has the affinity for toxins and 
thus becomes harmful in the body. 
Rectum being rich in vasculature and the unique 
preparations of Nirooha Yoga, the drugs are absorbed 
and cross the rectal mucosa through selective 
permeability. The major active principles present in the 
above formulation are of alkaline nature. This 
normalizes physiological PH of rectal mucosa facilitating 
for growth of bacterial flora which results in the 
stimulation of enzymes for the proper metabolism of 
cholesterol in to corpasterol. Most of the ingredients 
used in the formulation have been screened for anti-
hyperlipidaemic activities. Honey was tested for anti-
hyperlipidaemic activity by pre-clinical trials on rats and 
proven efficacious.27,28. Sesame protein isolated from 
Sesamum indicum found to be producing the anti-
hyperlipidaemic activity in normal and high cholesterol 
diet fed rats29. A study established hypolipidaemic 
activity of Triphala in an experimentally induced 
hypercholesteremic rats on all the lipids and free fatty 
acids30. As mentioned above it is proposed that the drugs 
absorbed either reaches portal circulation through 
superior haemorohoidal veins from upper rectal mucosa 
or directly enters into the systemic circulation through 
middle and inferior rectal veins from lower rectal 
mucosa. These active principles that reaches liver, 
stimulates production of bile salts resulting in 
regularization of emulsification of fats thus avoiding 
fatty accumulation in liver and in blood cells. The active 
principles directly entering in to circulation reduces the 
density of blood (Sandrata) by scraping the lipids in 
blood vessels with their alkaline property. Thus avoids 
the narrowing of arteries (atherosclerosis) which is 
major risk factor of CHD. 
Large intestine contains maximum number of 
nerve plexuses and lumbo sacral plexus that spread all 
over the body. Vata Dosha is considered to be the entity 
of functions performed by the above plexuses in the 
present context. Here by the virtue of Basti treatment 
Vata is channelized, causing stimulation of particular 
endocrine glands to release their enzymes like 
pancreatic lipase, acetyl-a coenzyme which are 
responsible for metabolism of lipids. Basti Dravyas are 
absorbed into Sira or Rasayani (channels) that generally 
carries Rasa along with Rakta. The increased Meda 
Dhatu also goes to Deha Sanchari (travel all over the 
body) through these Sira and Rasayini. It is perceived as 
increased lipids circulating through Rasa and Rakta. 
Hence the drugs administered in the form of Basti have 
effect even on Rakta Dhatu which is having the increased 
circulating lipids. Contributions in genetic factors - The 
gene responsible for familial hyperlipidaemia produces 
defective L.D. L receptors the cell to catch hold of the 
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LDL cholesterol. Thus results in the accumulation of LDL 
cholesterol and rapid buildup of fatty deposits in the 
arteries. Genes are mainly made up of protein molecules; 
even the Basti formulation administered was rich in 
protein. So it may alter the genetic code and 
development of proper receptors resistant lipase etc., 
that might have occurred which is yet to be tested for 
significances. 
Alteration of Dose: The Yoga possesses Teekshana 
Dravyas (most strong and potent). The doses of 
ingredients are altered to Avara Pramana (lower dose) 
as the actual classical dose was not tolerable by the 
patients in the pilot study. The altered dose is according 
to the Avara Pramana specified for Basti in Avara Bala 
patients which suits for present generations.31  
ADVERSE EVENTS 
Mild abdominal pain was observed which was 
spontaneously resolved after intake of food or after 
administration of Anuvasana Basti. Few females were 
presented with pre-ponement of the menstrual cycles 
followed by the course of Basti treatment.  
CONCLUSION 
This study concludes that, Ooshakadi Lekhana 
Basti to be effective in hyperlipidaemia and found to be 
more efficacious in the group of non-obese 
hyperlipidaemia patients. HDL was found to be 
increased along with the reduction of other lipids. The 
Ooshaka drug was found to be safe though it was highly 
alkaline in nature. 
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Graph-1: Showing the incidence and overall response in age of group 1 & 2  Graph-2: For group 3 
  
 
Graph-3: Showing the incidence in sex   Graph-4: Showing the incidence in sex and age 
   
 
Graph-5: Showing the incidence and                   Graph-6: Showing the incidence and overall  
Over all response in occupational status    response in socio-economic status 
     
 
Graph-7: Showing the incidence of Positive (Yes)                        Graph-8: Showing the incidence and overall 
and negative (No) family history                    response of Agni of the patient
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Graph-9:   Showing the incidence and                                           Graph-10: Showing the incidence of Predominant                      
Overall response of Koshta of the patient        Rasa 
       
 
Graph – 11: Showing the incidence of in Nidra  Graph -12: Showing the incidence of Vyasana 
       
 
Graph -13: Showing the incidence and                                    
overall response of Prakruti of the patient                           Graph-14: Showing Response of lipids in group 1&2                      
            
 
     Graph-16: Showing response of cholesterol  
Graph-15: Showing Response of lipids in group 3      in group 1 & 2 & Group 3 
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Graph-17: Showing response of triglycerides in     Graph-18: Showingresponse of H.D.L group 1 & 2 and 
group 3         in group 1 & 2 and group 3 
              
 
 
Graph-19: Showing response of L.D.L        Graph-20: Showing response of V. L.D.L 
In group 1 & 2 and group 3         in group 1 & 2 and group 3 
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